Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Gilmartin

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Molecular Cancer Therapeutics|June 24, 2010
Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instabilityYan Degenhardt, Joel Greshock, Sylvie Laquerre, et al.
Cancer Research|August 20, 2009
Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosisAidan G Gilmartin, Maureen R Bleam, Mark C Richter, et al.
Haematologica|June 27, 2020
<i>In vitro</i> and <i>in vivo</i> induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitorAidan G Gilmartin, Arthur Groy, Elizabeth R Gore, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)Hiroyuki Abe, Shinichi Kikuchi, Kazuhide Hayakawa, et al.
Nature Chemical Biology|January 7, 2014
Allosteric Wip1 phosphatase inhibition through flap-subdomain interactionAidan G Gilmartin, Thomas H Faitg, Mark Richter, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 20, 2010
Antitumor activity of an allosteric inhibitor of centromere-associated protein-EKenneth W Wood, Latesh Lad, Lusong Luo, et al.
Nature Cancer|November 18, 2021
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemiaMelissa B Pappalardi, Kathryn Keenan, Mark Cockerill, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Molecular Cancer Therapeutics|June 24, 2010
Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instabilityYan Degenhardt, Joel Greshock, Sylvie Laquerre, et al.
Cancer Research|August 20, 2009
Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosisAidan G Gilmartin, Maureen R Bleam, Mark C Richter, et al.
Haematologica|June 27, 2020
<i>In vitro</i> and <i>in vivo</i> induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitorAidan G Gilmartin, Arthur Groy, Elizabeth R Gore, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)Hiroyuki Abe, Shinichi Kikuchi, Kazuhide Hayakawa, et al.
Nature Chemical Biology|January 7, 2014
Allosteric Wip1 phosphatase inhibition through flap-subdomain interactionAidan G Gilmartin, Thomas H Faitg, Mark Richter, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 20, 2010
Antitumor activity of an allosteric inhibitor of centromere-associated protein-EKenneth W Wood, Latesh Lad, Lusong Luo, et al.
Nature Cancer|November 18, 2021
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemiaMelissa B Pappalardi, Kathryn Keenan, Mark Cockerill, et al.
Pageof 4